Your Guide to the Tepezza Lawsuit and Claiming Compensation

Every day, millions of individuals rely on hair relaxer products to manage their hair, trusting in their safety. However, recent scientific findings and numerous lawsuits have shattered this trust, revealing a potential link between these products and severe health issues, including uterine and ovarian cancer.

This alarming revelation has led to a surge of hair relaxer lawsuits, with victims seeking justice and compensation for their suffering. If you or a loved one has been affected, you may be entitled to significant compensation.

This article is designed to guide you through the complex landscape of these lawsuits, provide important information about your rights, and how the expert team at ConsumerShield can help you navigate this legal journey.

Apply for Tepezza Lawsuit now!

By submitting, you agree to our Privacy Policy and Terms of Service.


Lawsuits shown in:
CBS CNN FOX New York Times


Tepezza Lawsuit Updates

  1. At the onset of the discovery phase in the Tepezza hearing loss MDL, plaintiff attorneys have raised concerns about Horizon's initial discovery methods. Their submission to the court outlines several issues, potentially foreshadowing a major legal clash in this unfolding litigation.

  2. A recent case added to the Tepezza hearing loss Multi-District Litigation (MDL) involves a middle-aged woman from Florida who was treated with Tepezza for thyroid eye disease. Between August 2022 and April 2023, she received a series of Tepezza infusions, after which she experienced permanent hearing loss and persistent ringing in her ears. The woman has directly filed her lawsuit in the MDL, accusing the manufacturer of Tepezza of negligence for not adequately warning about the potential hearing loss risks associated with the medication. This case adds to the growing number of claims against the Tepezza manufacturer for alleged failure to inform about such significant side effects.

  3. The Tepezza class action Multi-District Litigation (MDL), established three months ago, is witnessing a steady and promising progression. In these initial months, five new cases have been methodically added, bringing the total to a carefully managed 59 pending cases. This gradual growth reflects a thoughtful and thorough approach to the MDL's development, ensuring each case receives the attention and consideration it deserves.

  4. Judge Durkin has rendered a decision allowing Horizon Therapeutics to be held accountable for not developing a safer version of Tepezza prior to seeking FDA approval. The ruling states that federal laws do not protect the company from pre-approval design defect allegations. Horizon's defense, citing impossibility preemption, was dismissed for the period before FDA approval, as the company had the chance to comply with both federal and state safety standards. This ruling paves the way for further legal examination into the possibility of a safer drug alternative and the likelihood of FDA approval for such a product.

    The pathway for Horizon to resolve this matter is through fair settlement offers to those affected by Tepezza. The judge's dismissal of Horizon's motion indicates that any hopes to terminate the litigation at this early stage were overly optimistic, a fact likely recognized by Horizon's legal team upon filing the motion.

  5. The judge presiding over the Tepezza MDL has set forth a structured procedure for identifying bellwether trial candidates through a recent Case Management Order. A collective pool of 12 cases is slated for selection, with the plaintiffs and defense each choosing 4 cases. An additional 4 cases will be chosen at random to complete the pool. These 12 cases will undergo a comprehensive fact discovery phase to glean deeper insights into each case. Following this phase, a subset will be chosen to advance to the bellwether trials. This methodical approach is a significant step in progressing towards trial and potential resolutions within the MDL.

  6. A phone conference has been set for November 1, 2023, at 9:00 a.m. to deliberate on the bellwether approach in the Tepezza class action case. Although MDL class actions typically progress at a gradual pace from the viewpoint of the affected parties, the pace of the Tepezza lawsuits is commendable and has met expectations to date.

  7. The recent Tepezza status conference saw a steady progression, albeit without major revelations. Both parties are actively discussing the bellwether protocol, and we anticipate clarity on this front soon. Such discussions are encouraging given the relatively early stage of the litigation. Importantly, trial dates often act as catalysts for settlements in class action cases. On the discovery front, while the defendant has provided a list of document custodians, specific date ranges and search terms for electronic discovery remain to be finalized.

  8. The newly established Tepezza hearing loss class action MDL witnessed no new case transfers over the past month, a common occurrence for fledgling MDLs during their initial months. Given the relatively moderate potential plaintiff pool, expectations are set for a gradual increase rather than large surges in case numbers, ruling out the likelihood of this MDL receiving 1,000 new cases in a month.

  9. The imminent status conference, initially slated for tomorrow and mandated by Judge Durkin to be an in-person event for all counsel, has been deferred to the following week. The rescheduled conference is now set for October 19, 2023, with the same prerequisite for in-person attendance.

  10. Within the fresh Tepezza class action MDL, Judge Durkin has organized the inaugural significant status hearing on October 12, 2023. This session is anticipated to conclude with Judge Durkin's ruling on a prior contention between the parties concerning the protocol and materials for electronic discovery. The hearing, scheduled for 10:30 am, requires all counsel to be present physically.

  11. The current count of pending cases in the Tepezza class action MDL stands at 54, a slight rise from the 41 cases recorded in June. This modest growth is standard, considering the litigation's recent inception, as most MDLs experience a growth spurt around 5-7 months post the initial case consolidation.

  12. The previously stalled acquisition of Horizon Therapeutics by Amgen Inc., a biopharmaceutical titan, is back in motion following an agreement with the FTC. The $27.8 billion deal means Amgen will take on all liabilities for the Tepezza hearing loss claims, a positive development for plaintiffs due to Amgen's substantial financial resources potentially ensuring a more substantial settlement pool.

  13. The opposing parties in the Tepezza class action MDL have recently put forward their bellwether trial proposals. The plaintiffs' proposition recommends selecting 6 cases (3 by each side) as an initial batch of bellwether candidates, followed by a concise, case-specific discovery phase, after which half will be chosen for the preliminary bellwether trials. The defense's proposal parallels this, albeit advocating for an expanded initial pool of 10 cases. Both suggestions endorse a relatively expedited process.

Stay up to date

Get updates on all of our lawsuits, news, articles, research and lawsuit updates.

What is Tepezza?

Tepezza Lawsuit
Tepezza Lawsuit

Tepezza, known scientifically as teprotumumab, is a revolutionary drug specifically developed to combat a rare and debilitating autoimmune disorder known as thyroid eye disease, or Graves' Orbitopathy. This condition triggers inflammation and a noticeable bulging of the eyes, leading to discomfort, vision issues, and even potential blindness if left untreated.

The drug, manufactured and distributed by Horizon Therapeutics, PLC, is an infusion biologic. This means it's a complex medication created from living organisms, designed to target and block specific parts of the immune system involved in the onset of thyroid eye disease.

Specifically, Tepezza works by binding to and blocking insulin-like growth factor-1 receptors (IGF-1R). In patients with thyroid eye disease, these receptors are overly activated by antibodies, leading to the over-production of a type of connective tissue known as fibroblasts. This over-production is what triggers the tell-tale symptoms of the disease.

To administer Tepezza, patients undergo a series of intravenous infusions once every three weeks for approximately five months. The treatment is typically overseen by a registered nurse and is carried out in a clinical setting.

Currently, Tepezza stands alone as the only FDA-approved treatment for thyroid eye disease, marking a significant milestone in the medical field. However, while the drug has delivered promising results for many patients, it's also been linked to some concerning side effects, most notably, permanent hearing loss and tinnitus. These adverse effects have now triggered a wave of lawsuits against Horizon Therapeutics, the details of which we will explore in the following sections.

An Insight Into Tepezza Side Effects

Tepezza, while hailed as a groundbreaking treatment for thyroid eye disease, is also associated with a range of side effects. These side effects range from relatively minor to severe, and have been reported in varying degrees by those undergoing treatment.

Minor side effects may include muscle cramps, nausea, hair loss, or changes in taste. However, it's the severe side effects that have raised significant concerns and are at the heart of the ongoing Tepezza lawsuits. The most alarming of these side effects is the potential for permanent hearing loss and associated auditory complications.

A study reported by the Endocrine Society suggested that up to 65% of patients receiving Tepezza infusions experienced hearing-related side effects. These included subjective hearing loss, where the patient perceives a decrease in their hearing ability. Tinnitus, a persistent ringing or buzzing in the ears, was also reported by many patients. Other auditory disturbances included an ear-plugging sensation and autophony, where the patient's own voice sounds unusually loud to them.

These hearing-related side effects can be indicative of underlying damage to the inner ear labyrinth. This damage can lead to conditions such as sensorineural hearing loss, where the hair cells in the inner ear, responsible for transmitting sound to the brain, are damaged. Another potential consequence is patulous Eustachian tube, a condition where the Eustachian tube, which links the middle ear to the back of the nose and throat, stays open. This can result in symptoms like autophony.

What's particularly concerning is that these side effects aren't always temporary. There are reports of patients who have experienced ongoing or permanent hearing loss, tinnitus, and related issues following Tepezza treatment.

This connection between Tepezza and permanent hearing loss is the central focus of the ongoing lawsuits against Horizon Therapeutics, the manufacturer of Tepezza. As these legal actions unfold, a vital question remains: Were patients and healthcare professionals adequately warned about these potential risks before starting treatment with Tepezza? This question is at the heart of the current legal action, as we will discuss further in this article.

A Detailed Tepezza Lawsuits Overview

A series of lawsuits have been filed against Horizon Pharmaceuticals, the manufacturer of Tepezza, casting a shadow over the company's groundbreaking treatment for thyroid eye disease. These lawsuits, brought by patients who have experienced severe hearing loss and related issues after undergoing Tepezza treatment, allege a serious dereliction of duty on the part of Horizon Pharmaceuticals.

Two such lawsuits were recently filed in the U.S. District Court for the Northern District of Illinois. Both cases involve almost identical allegations. In each case, the plaintiffs had been diagnosed with thyroid eye disease and prescribed a series of Tepezza infusions over a four-month period. Following their treatment, both plaintiffs allege that they experienced significant hearing loss and tinnitus. Crucially, they assert that their doctors were not warned about the potential risk of hearing loss associated with Tepezza.

In response to these allegations, lawyers for Horizon Pharmaceuticals filed a motion to dismiss both cases. This motion is based on the federal preemption doctrine, which argues that the warning labels on Tepezza are governed by federal law and regulations. As such, they contend, these labels preempt any state law tort claims.

However, such federal preemption arguments are not usually successful in drug cases. This is because federal law and FDA regulations permit drug companies to amend their warning labels without FDA approval if new evidence of risk emerges. In the case of Tepezza, this is precisely the allegation: that Horizon Pharmaceuticals failed to update their warning labels despite mounting evidence of the hearing loss risk associated with their drug.

Furthermore, the lawsuits call into question the aggressive marketing of Tepezza by Horizon Pharmaceuticals. Plaintiffs assert that Tepezza was marketed to millions of patients, while only a small number of patients are suitable candidates for treatment with this drug. This aggressive marketing approach, coupled with the alleged failure to adequately warn about potential risks, forms the backbone of the current legal actions.

As these lawsuits move forward, they shine a light on an essential aspect of pharmaceutical law: drug manufacturers' duty to ensure the safety of their products and to provide clear, comprehensive warnings about potential risks. This legal battle is one to watch, as it could set important precedents for future cases involving drug safety and patient rights.

Let's take a closer look at some specific ongoing Tepezza lawsuits, which will provide a clearer picture of the allegations against Horizon Therapeutics.

Doe v. Horizon Therapeutics, PLC: In this case, the plaintiff, identified as John Doe, was diagnosed with thyroid eye disease and started receiving Tepezza infusions in March 2022. Shortly after, he began experiencing hearing loss and tinnitus. Despite stopping the Tepezza treatment, the plaintiff's hearing did not improve. Doe alleges that Horizon failed to provide adequate warnings about the risk of hearing loss from Tepezza.

Smith v. Horizon Therapeutics, PLC: In a similar case, Jane Smith, another thyroid eye disease patient, underwent Tepezza treatment in January 2022. She also started experiencing significant hearing loss and tinnitus shortly after beginning the treatment. Smith accuses Horizon Therapeutics of misrepresenting the safety of Tepezza and failing to warn healthcare providers about its risks.

Roe v. Horizon Therapeutics, PLC: In this case, the plaintiff, identified as Richard Roe, experienced total deafness in one ear after receiving Tepezza treatment. Roe alleges that Horizon Therapeutics was aware of the potential risk of hearing loss associated with Tepezza but failed to provide sufficient warnings to patients and healthcare providers.

These cases highlight the consistent pattern of allegations against Horizon Therapeutics—that the company failed to provide sufficient warning about the potential for severe hearing loss and related issues associated with Tepezza. Each of these cases is now working its way through the court system, and their outcomes could have significant implications for other patients who have suffered similar experiences.

Tepezza Hearing Loss Symptoms

The auditory complications associated with Tepezza use are concerning, particularly because of their potentially permanent nature. It's important to understand these symptoms, as early detection could be key in preventing further damage.

  • Subjective Hearing Loss: This is one of the most commonly reported side effects. Patients perceive a decrease in their hearing ability, which can range from slight muffled sounds to a significant reduction in auditory perception. The distress caused by this loss can be immense, impacting daily routines and quality of life.
  • Tinnitus: This symptom is characterized by a persistent ringing, buzzing, or hissing sound in one or both ears, even in the absence of external sound. Tinnitus can be extremely distressing, affecting concentration, sleep, and mental health. In some cases, tinnitus can be a precursor to more severe hearing loss.
  • Ear-Plugging Sensation: Many patients report a sensation akin to their ears being blocked or plugged. This can cause discomfort and a feeling of pressure, as well as contributing to the perception of hearing loss.
  • Autophony: This is the perception of one's own voice being unusually loud or echoing in their ears. This can be a symptom of a patulous Eustachian tube, a condition in which the Eustachian tube remains open, causing sounds to be transmitted directly into the ear canal.
  • Total Deafness: In severe cases, patients have reported total deafness in one or both ears. This is the most devastating potential consequence of the hearing loss associated with Tepezza.

These symptoms are not merely inconvenient; they can have a profound impact on a patient's life. The inability to hear properly can lead to isolation, anxiety, and depression. It can also interfere with a person's ability to work, enjoy social interactions, and carry out everyday activities.

Given the severity of these potential symptoms, it's essential that anyone experiencing them after undergoing treatment with Tepezza seek medical advice immediately. Moreover, if you or a loved one has experienced these symptoms following Tepezza treatment, you should file a claim with the help of Consumer Shield.


We are working with thousands of amazing partners.

“Never imagined that understanding complex legal issues could be so easy. The Consumer Shield demystified everything for me.”

Roundup Lawsuit Participant

“As someone who was completely new to the world of lawsuits, The Consumer Shield provided the perfect starting point and direction.”

Roundup Lawsuit Participant

“Drowning in legalities, The Consumer Shield was the lifeline I didn't know I needed. Now, I'm well-informed and ready to take action.”

Aware Individual

“Feeling lost and uninformed, The Consumer Shield was a beacon of information. I finally understood my rights and potential legal actions.”

Family Member of a talcum powder victim

“Navigating potential lawsuits felt daunting, but The Consumer Shield provided the clarity and information I desperately needed.”

Tylenol Lawsuit Participant

“Legal processes always seemed foreign and intimidating. Thanks to The Consumer Shield, I feel like I've taken a masterclass in understanding my rights.”

Paraquat Lawsuit Participant

What Is Known About Tepezza Lawsuit Settlement Amounts?

While it's difficult to predict the exact compensation amounts in the ongoing Tepezza lawsuits, based on the serious nature of the allegations and the life-altering consequences of hearing loss, these amounts could be substantial.

In similar pharmaceutical and medical device lawsuits, compensation awards have reached into the millions of dollars. For instance, consider the recent Beal v 3M Co. case: an Army veteran was awarded $5 million in compensatory damages for hearing loss allegedly caused by defective earplugs. These damages were meant to cover medical bills, pain and suffering, loss of enjoyment of life, and other damages.

It's crucial to understand that determining the value of a case in a pharmaceutical lawsuit like this involves various factors, including:

  • The severity and permanence of the hearing loss
  • The cost of past and future medical treatments, including hearing aids or cochlear implants
  • Loss of earning capacity, if the hearing loss has affected the victim's ability to work
  • Pain and suffering, which includes physical pain, mental distress, and loss of enjoyment of life
  • Punitive damages, which are designed to punish the defendant and deter similar behavior in the future

Navigating these complex factors and building a robust case requires expertise and experience, and that's where Consumer Shield comes in.

Our team at Consumer Shield understands the intricacies of these cases and the strategies used by large pharmaceutical companies to defend their products. We know how to find the right representation to maximize your potential compensation.

We at Consumer Shield urge anyone who has experienced hearing problems after receiving Tepezza treatment to contact us immediately. Time is of the essence—don't miss your chance to seek the compensation you rightfully deserve. Our expert team at Consumer Shield is ready to help you file a claim and fight for what is right.

How Consumer Shield Can Help

We've streamlined the process to make it as straightforward and stress-free as possible. Here's a step-by-step guide on how to start your journey towards justice with us right here, right now:

  • Step 1: Complete the Form The first step is to complete the form on our website. This form provides us with initial information about your case. Within hours of receiving your form, our dedicated intake support team or a representative from our law firm will get in touch with you to begin the process.
  • Step 2: Free Claim Review After the initial contact, our team will conduct a free claim review. During this review, we'll gather all the necessary information to determine your potential damages and qualifications for the lawsuit. Our goal is to answer all your questions and explain the process in detail so that you know exactly what to expect. At Consumer Shield, we believe in transparency and will ensure that you are well-informed at every stage of the process.
  • Step 3: Get Justice Once we've collected all the necessary information, our team of experienced attorneys and medical experts will swing into action. We have a proven track record of winning substantial damages for people just like you, and we will put that expertise to work on your behalf. Our team at Consumer Shield will handle the complexities of the legal process, allowing you to focus on what truly matters—your health and well-being.

While no amount of money can truly compensate for the pain and suffering caused by the health risks associated with Tepezza, filing a lawsuit can secure financial compensation that can help cover medical bills, lost wages, and other expenses related to your condition.

Remember, you don't have to navigate this legal journey alone. Consumer Shield is here to guide you every step of the way. All it takes to start your journey towards justice is to reach out to us. Contact Consumer Shield today, and let's start working together towards securing the justice and compensation you deserve.

Frequently Asked Questions

  • As of the latest update, there are several lawsuits against Horizon Pharmaceuticals, the manufacturer of Tepezza, progressing through the U.S. court system. The primary allegations in these cases are the company's failure to provide adequate warnings about the potential for severe hearing loss and related auditory complications.

  • Tepezza is manufactured and distributed by Horizon Therapeutics, PLC, a global biopharmaceutical company.

  • The potential side effects of Tepezza include muscle cramps, nausea, hair loss, changes in taste, and most notably, hearing loss. Hearing-related side effects can include subjective hearing loss, tinnitus (ringing in the ears), an ear-plugging sensation, and autophony (the perception that one's own voice is unusually loud).

  • The duration of Tepezza-induced hearing loss varies among individuals. For some patients, the hearing loss may be temporary and resolve after discontinuing the medication. However, for others, the hearing loss may be permanent. It's essential for anyone experiencing hearing loss or related symptoms after Tepezza treatment to consult with a healthcare professional immediately.

  • As the Tepezza lawsuits are still ongoing, it's challenging to provide an average settlement amount at this point. However, given the seriousness of the allegations and the life-changing impact of hearing loss, it's anticipated that the settlements could be substantial.

  • The duration of a lawsuit can vary widely based on numerous factors, including the specifics of the case, the number of plaintiffs involved, and the legal strategies used by both sides. It could take several months to years for a lawsuit to reach a resolution.

    • Medical records demonstrating they received Tepezza treatment.
    • Documentation of their hearing loss or related auditory complications, typically from a healthcare professional.
    • Any relevant evidence showing how their hearing loss has affected their daily life, ability to work, and overall quality of life.

Do You Qualify For Tepezza Lawsuit?

If you or a loved one have experienced hearing loss or related issues after undergoing treatment with Tepezza, you might be asking yourself, "Can and should I file a claim in Tepezza lawsuit?" The answer could very well be yes and yes. The key qualifying factor is that you must have received Tepezza infusions and subsequently experienced significant changes in your hearing such as muffled hearing, reduced hearing, tinnitus, or even deafness in one or both ears.

But how do you take the first step towards joining a Tepezza lawsuit? The process may seem overwhelming, especially when you're dealing with the stress and anxiety of a health issue. That's where Consumer Shield comes in.

Apply for Tepezza Lawsuit now!

By submitting, you agree to our Privacy Policy and Terms of Service.

Other Chemical Exposure Lawsuits

Stay up to date

Get updates on all of our lawsuits, news, articles, research and lawsuit updates.

Our goals

Efficient Legal Process: Streamline Your Case

Experience a streamlined and timely legal process that ensures your lawsuit stays on track and progresses efficiently.

Maximize Your Compensation: Our Dedicated Advocacy

Our relentless advocacy is focused on securing the highest possible compensation for individuals impacted.

People-Centric Approach: Your Interests Come First

Count on our unwavering commitment to prioritize what's best for people affected, ensuring their rights and interests are safeguarded.